Black Diamond Therapeutics (NASDAQ:BDTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
Valuation & Earnings
This table compares Black Diamond Therapeutics and Cardiff Oncology’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Diamond Therapeutics | N/A | N/A | -$67.25 million | ($3.39) | -1.77 |
| Cardiff Oncology | $370,000.00 | 600.76 | -$19.31 million | ($0.67) | -8.39 |
Cardiff Oncology has higher revenue and earnings than Black Diamond Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Black Diamond Therapeutics and Cardiff Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
| Cardiff Oncology | 0 | 0 | 2 | 0 | 3.00 |
Black Diamond Therapeutics currently has a consensus price target of $33.80, indicating a potential upside of 463.33%. Cardiff Oncology has a consensus price target of $25.00, indicating a potential upside of 344.84%. Given Black Diamond Therapeutics’ higher probable upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Cardiff Oncology.
Risk & Volatility
Black Diamond Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Profitability
This table compares Black Diamond Therapeutics and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -46.24% | -40.62% |
| Cardiff Oncology | -7,375.65% | -19.37% | -18.53% |
Institutional and Insider Ownership
69.9% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 67.0% of Cardiff Oncology shares are owned by institutional investors. 5.2% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Cardiff Oncology beats Black Diamond Therapeutics on 7 of the 13 factors compared between the two stocks.
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cardiff Oncology Company Profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm’s clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.